FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2735948696> ?p ?o ?g. }

• W2735948696 endingPage "10500" @default.
• W2735948696 startingPage "10500" @default.
• W2735948696 abstract "10500 Background: In 2004 we launched an open-label randomized trial with adjuvant IM for 2 yrs in localized, surgically resected, high/intermediate-risk GIST. Methods: Pts were randomized between 2 yrs of IM, 400 mg daily, and no further therapy after surgery. The primary end-point was OS, while RFS, RFI and toxicity were secondary end-points. Main eligibility criteria were: age >18 yrs, PS 0-2, localized CD117-positive GIST, intermediate or high risk according to the 2002 Consensus classification, R0 or R1 surgical margins, no previous medical therapy. Pts were stratified by risk, tumor site and margins. An accrual of 400 pts was planned, then escalated to 900. Given the prognostic improvement of advanced GIST pts, in 2009 the study IDMC authorized to change the primary end-point into IFS, whose failure was defined as the time when a different tyrosine kinase inhibitor (TKI) is started. We report on a planned interim analysis carried out after 115 events according to the new primary end-point, with a significance level of 1.5%. Hazard ratios (HR) and p-values were adjusted for stratification factors. Results: 908 pts were randomized between 2005 and 2008, 454 to IM and 454 to observation arm; 835 pts were eligible. 17% of pts treated with IM stopped early due to toxicity or refusal. With a median follow-up of 4.7 yrs, 5-yr IFS was 87% in the IM-arm vs 84% in the control arm (HR=0.80, 98.5% CI [0.51; 1.26], p=0.23); RFS was 84% vs 66% at 3 yrs, and 69% vs 63% at 5 yrs (p<0.001); 5-yr OS was 100% vs 99%. Among 528 pts with high-risk GIST by local pathology, 5-yr IFS was 79% vs 73% (p=0.11), and 77% vs 73% (p=0.44) amongst 336 high-risk GIST pts by centrally reviewed pathology. Conclusions: This study confirms that adjuvant IM has an overt impact on short-term freedom from relapse. In the high-risk subgroup, a non-statistically significant trend in favor of the adjuvant arm was observed in terms of IFS. This new end-point for the adjuvant setting, i.e. survival free from any failure of the first employed TKI, was designed to incorporate secondary resistance, i.e. the currently main factor adversely affecting prognosis of advanced GIST pts. Clinical trial information: NCT00103168." @default.
• W2735948696 created "2017-07-21" @default.
• W2735948696 creator A5008173055 @default.
• W2735948696 creator A5016161312 @default.
• W2735948696 creator A5042202815 @default.
• W2735948696 creator A5046159238 @default.
• W2735948696 creator A5046601855 @default.
• W2735948696 creator A5046831977 @default.
• W2735948696 creator A5050786772 @default.
• W2735948696 creator A5052972588 @default.
• W2735948696 creator A5053304892 @default.
• W2735948696 creator A5054968300 @default.
• W2735948696 creator A5055163903 @default.
• W2735948696 creator A5060949051 @default.
• W2735948696 creator A5061157288 @default.
• W2735948696 creator A5066380305 @default.
• W2735948696 creator A5082287639 @default.
• W2735948696 creator A5090103193 @default.
• W2735948696 creator A5091114658 @default.
• W2735948696 date "2013-05-20" @default.
• W2735948696 modified "2023-10-17" @default.
• W2735948696 title "Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial." @default.
• W2735948696 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.10500" @default.
• W2735948696 hasPublicationYear "2013" @default.
• W2735948696 type Work @default.
• W2735948696 sameAs 2735948696 @default.
• W2735948696 citedByCount "33" @default.
• W2735948696 countsByYear W27359486962013 @default.
• W2735948696 countsByYear W27359486962014 @default.
• W2735948696 countsByYear W27359486962015 @default.
• W2735948696 countsByYear W27359486962016 @default.
• W2735948696 countsByYear W27359486962017 @default.
• W2735948696 countsByYear W27359486962018 @default.
• W2735948696 countsByYear W27359486962019 @default.
• W2735948696 countsByYear W27359486962022 @default.
• W2735948696 countsByYear W27359486962023 @default.
• W2735948696 crossrefType "journal-article" @default.
• W2735948696 hasAuthorship W2735948696A5008173055 @default.
• W2735948696 hasAuthorship W2735948696A5016161312 @default.
• W2735948696 hasAuthorship W2735948696A5042202815 @default.
• W2735948696 hasAuthorship W2735948696A5046159238 @default.
• W2735948696 hasAuthorship W2735948696A5046601855 @default.
• W2735948696 hasAuthorship W2735948696A5046831977 @default.
• W2735948696 hasAuthorship W2735948696A5050786772 @default.
• W2735948696 hasAuthorship W2735948696A5052972588 @default.
• W2735948696 hasAuthorship W2735948696A5053304892 @default.
• W2735948696 hasAuthorship W2735948696A5054968300 @default.
• W2735948696 hasAuthorship W2735948696A5055163903 @default.
• W2735948696 hasAuthorship W2735948696A5060949051 @default.
• W2735948696 hasAuthorship W2735948696A5061157288 @default.
• W2735948696 hasAuthorship W2735948696A5066380305 @default.
• W2735948696 hasAuthorship W2735948696A5082287639 @default.
• W2735948696 hasAuthorship W2735948696A5090103193 @default.
• W2735948696 hasAuthorship W2735948696A5091114658 @default.
• W2735948696 hasConcept C10205521 @default.
• W2735948696 hasConcept C121608353 @default.
• W2735948696 hasConcept C126322002 @default.
• W2735948696 hasConcept C141071460 @default.
• W2735948696 hasConcept C143998085 @default.
• W2735948696 hasConcept C168563851 @default.
• W2735948696 hasConcept C16930146 @default.
• W2735948696 hasConcept C203092338 @default.
• W2735948696 hasConcept C207103383 @default.
• W2735948696 hasConcept C2775922572 @default.
• W2735948696 hasConcept C2776839831 @default.
• W2735948696 hasConcept C2777583451 @default.
• W2735948696 hasConcept C2777982462 @default.
• W2735948696 hasConcept C2778729363 @default.
• W2735948696 hasConcept C28328180 @default.
• W2735948696 hasConcept C44249647 @default.
• W2735948696 hasConcept C54355233 @default.
• W2735948696 hasConcept C61943457 @default.
• W2735948696 hasConcept C71924100 @default.
• W2735948696 hasConcept C86803240 @default.
• W2735948696 hasConcept C90924648 @default.
• W2735948696 hasConceptScore W2735948696C10205521 @default.
• W2735948696 hasConceptScore W2735948696C121608353 @default.
• W2735948696 hasConceptScore W2735948696C126322002 @default.
• W2735948696 hasConceptScore W2735948696C141071460 @default.
• W2735948696 hasConceptScore W2735948696C143998085 @default.
• W2735948696 hasConceptScore W2735948696C168563851 @default.
• W2735948696 hasConceptScore W2735948696C16930146 @default.
• W2735948696 hasConceptScore W2735948696C203092338 @default.
• W2735948696 hasConceptScore W2735948696C207103383 @default.
• W2735948696 hasConceptScore W2735948696C2775922572 @default.
• W2735948696 hasConceptScore W2735948696C2776839831 @default.
• W2735948696 hasConceptScore W2735948696C2777583451 @default.
• W2735948696 hasConceptScore W2735948696C2777982462 @default.
• W2735948696 hasConceptScore W2735948696C2778729363 @default.
• W2735948696 hasConceptScore W2735948696C28328180 @default.
• W2735948696 hasConceptScore W2735948696C44249647 @default.
• W2735948696 hasConceptScore W2735948696C54355233 @default.
• W2735948696 hasConceptScore W2735948696C61943457 @default.
• W2735948696 hasConceptScore W2735948696C71924100 @default.
• W2735948696 hasConceptScore W2735948696C86803240 @default.
• W2735948696 hasConceptScore W2735948696C90924648 @default.
• W2735948696 hasIssue "15_suppl" @default.
• W2735948696 hasLocation W27359486961 @default.

• next